PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Revenue growth exceeding 1.5x AGEN's 24.65%. David Dodd would verify if faster growth reflects superior business model.
-27.15%
Cost reduction while AGEN shows 31.63% growth. Joel Greenblatt would examine competitive advantage.
73.30%
Positive growth while AGEN shows decline. John Neff would investigate competitive advantages.
89.46%
Margin expansion while AGEN shows decline. John Neff would investigate competitive advantages.
8.30%
R&D growth less than half of AGEN's 271.20%. David Dodd would verify if efficiency advantage is sustainable.
28.80%
Similar G&A growth to AGEN's 38.28%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth less than half of AGEN's 38.28%. David Dodd would verify sustainability.
14.70%
Total costs growth less than half of AGEN's 33.50%. David Dodd would verify sustainability.
-100.00%
Interest expense reduction while AGEN shows 11.01% growth. Joel Greenblatt would examine advantage.
-27.15%
D&A reduction while AGEN shows 10.66% growth. Joel Greenblatt would examine efficiency.
-16.20%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
54.13%
EBITDA margin growth while AGEN declines. John Neff would investigate advantages.
-15.23%
Both companies show declining income. Martin Whitman would check industry conditions.
54.52%
Operating margin growth while AGEN declines. John Neff would investigate advantages.
98.15%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
-12.38%
Both companies show declining income. Martin Whitman would check industry conditions.
55.64%
Pre-tax margin growth while AGEN declines. John Neff would investigate advantages.
-98.15%
Tax expense reduction while AGEN shows 32.64% growth. Joel Greenblatt would examine advantage.
-9.33%
Both companies show declining income. Martin Whitman would check industry conditions.
56.84%
Net margin growth while AGEN declines. John Neff would investigate advantages.
-5.41%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-8.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.98%
Share count reduction exceeding 1.5x AGEN's 7.64%. David Dodd would verify capital allocation.
2.03%
Diluted share reduction exceeding 1.5x AGEN's 7.64%. David Dodd would verify capital allocation.